Kornimate/medical-research-clean huggingface dataset:
very rapid and rapid virological response as predictors of response of hcv tretment

Conditions: Predictors of Response to HCV Tretment

Summary: assessment of very rapid virological response and rapid virological response as predictors of response to sofosbuvir and daclatasvir in treatment of cirrhotic and non-cirrhotic patients with hcv, eligible to treatment.

chronic hepatitis c infection (chc) is a global health problem, with an estimated 120 to 130 million chronic hepatitis c virus (hcv) carriers worldwide therefore, early recognition and effective management of the disease can modify its natural history . there is a growing body of evidence that suggests that treatment will help reduce liver inflammation, may reverse liver damage (scarring),slow down disease progression and improve symptoms and quality of life. all of these factors are important reasons to seek hcv medical treatment identifying host-viral factors that predict the likelihood of svr prior to initiating therapy would be a very useful clinical tool that could help reduce costs and avoid unnecessary exposure to therapy with significant side effects little is known about predictors of failure to achieve svr with daas. although numerous clinical parameters predicted poor response to pegylated ifn treatment , none of them have been shown to be associated with virological relapse after daa based therapy treatment response terms: the ultra rapid virological response (urvr) is a new endpoint that we defined as an undetectable serum hcv rna at the end of 1st week of therapy. the very rapid virologic response( vrvr )defined as undetectable serum hcv rna level at week 2. the rapid virological response (rvr) defined as undetectable serum hcv rna after 4 weeks of treatment sustained virological response (svr), which is defined by the undetectable serum hcv rna 12-24 weeks after the end of treatment relapser was defined as undetectable viral load at the end of daa treatment but subsequent detectable viral load at 12 weeks after treatment end.

Eligibility criteria:
inclusion criteria: * anti hcv positive patients either chronic hcv or liver cirrhosis. * detectable hcv rna by quantitative pcr prior to treatment. * naïve patients (not received any hcv treatment regimen before) exclusion criteria: * patients with hepatocellular carcinoma( hcc) * patients with combined hbv and hcv
comparison of two protocols on the implementation of a fasting day in type 1 diabetes

Conditions: Fasting

Summary: this is a prospective study with a "crossover design", where fasting with a day of complete fasting and a fasting day with the permission intake of calories- and carbohydrate-free foods are compared in a randomized order. underlying hypothesis is that at the same basal insulin substitution with the fasting of both protocols , no significant differences in the glucose-day or -night profiles revealed. so the same conclusions regarding the "consistency" of basal insulin dosing revealed during the implementation of the part of patients is rated as more pleasant when calories and carbohydrates-free food are allowed.


Eligibility criteria:
inclusion criteria: * type 1 diabetes * basal insulin substitution with neutrales protamin hagedorn (nph) -insulin (at least twice a day), insulin detemir (twice a day), insulin glargine (once or twice a day) or with insulin pump * diabetes duration \> 2 years * body-mass-index between 19 and 35 kg/m², including * written consent exclusion criteria: * no pregnancy in woman
prevalence of critical forms of covid-19 in patients with chronic respiratory disease

Conditions: COVID

Summary: a new coronavirus (sars-cov-2) emerged in wuhan province, china in december 2019 and rapidly spread around the world. to date, the data in the literature regarding the clinical and epidemiological characteristics of severe forms of covid-19 in patients with chronic respiratory disease are not well known. the hypothesis is that patients with chronic respiratory disease (copd, asthma, bronchial dilatations, pulmonary hypertension, cystic fibrosis, obesity-hypoventilation syndrome, obstructive sleep apnea syndrome) infected with sars-cov-2 will have increased dyspnea and hypoxemia leading to hospitalization for severe forms more frequently than the general population. however, they do not appear to be more at risk of developing a critical form. this study is carried out in order to propose to estimate the prevalence of critical forms of covid19 among patients with chronic respiratory diseases hospitalized for severe forms.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years of age * diagnosis of covid-2 sars infection retained (from clinical presentation, radiological and covid-19 positive microbiological specimen). * hospitalisation in the conventional medical sector for "respiratory" reasons (= severe form of covid-19) in the nancy-brabois hospital and metz-thionville hospital between 02/03/2020 and 15/06/2020. exclusion criteria: * diagnosis of sars-cov-2 infection not retained * refusal of the patient to participate in the study * persons referred to in articles l. 1121-5, l. 1121-7 and l1121-8 of the public health code: o pregnant woman, parturient or breastfeeding mother o minors (not emancipated) o persons of full age subject to a legal protection measure (guardianship, curatorship, safeguard of justice) - persons of full age unable to express their consent persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care by virtue of articles l. 3212-1 and l. 3213-1.
effectiveness of mechano-analgesia and cold application on ecchymosis, pain and satisfaction at subcutaneous heparin injection

Conditions: Injection Site Reaction; Injection Site Bruising

Summary: fifty-five patients received three subcutaneous heparin injections (165 injections) by the same investigator using additional techniques such as mechano-analgesia and cold application, and without any additional techniques.

the abdomen was divided into four quarters. the first, second, and third sc heparin injections were applied from the right abdominal region using shotblocker®, left abdominal region with an ice pack, and lower abdominal region without any additional application, respectively. all the injection sites were circled using a skin marking pen (r = 5 cm). all the injections were administered following a standard procedure. pain and satisfaction were assessed immediately after the injection by using the vas score. ecchymosis was assessed with an ecchymosis measurement tool at 48 and 60 hours after the injection (figure 3).

Eligibility criteria:
inclusion criteria: * must be older than 18 years * open to communication * no complications during the operation * normal body mass index (bmi; reference range, 18.5-29.9 kg/m2) (d) and * platelet count (150.000-300.000) * give consent to participate in the study exclusion criteria: * oral and parenteral anticoagulant treatment for at least 5 days * infection, scar tissue or incision, and parenteral treatment in their abdominal area * hematological and allergic disease

Keywords: subcutaneous heparin injection pain ecchymosis
prophylaxis of chb patients with malignant tumor receiving chemotherapy

Conditions: Hepatitis B, Chronic; Tumor

Summary: to evaluate the effectiveness and safety of tenofovir for different treatment duration in preventing hbv relapse in patients with malignancies after receiving chemotherapy and off-treatment of chemotherapy.

this study aims to evaluate the effectiveness and safety of tenofovir in preventing hbv relapse in hbv carriers with malignant tumor following chemotherapy. approximately 100 patients who are planned to receive chemotherapy for malignant tumor will be invited to participate in this trail. a 1 or less 1-week tenofovir prophylaxis treatment should be administered by all subjects prior to the chemotherapy and eligible subjects will be randomly assigned to extend 24-week prophylaxis group a or 48-week prophylaxis group b in a 1:1 ratio at the end of the chemotherapy. the subjects could be stopped or withdrawn from this study earlier if hbv relapses or need to receive another course of chemotherapy respectively. the relapse episode will be followed until 24 weeks after the end of prophylaxis therapy. data collection will take place at screening, every cyclic visit of chemotherapy, at the end of chemotherapy, and the following prophylaxis period, then every 4 weeks during the follow-up period. patients in both groups will be treated with tenofovir or other antiviral agent according to investigator judgement when hbv relapse after discontinuation of tenofovir therapy.

Eligibility criteria:
inclusion criteria: 1. male or female 18 to 70 years of age 2. patients with histologically proven malignant tumor planned to receive chemotherapy after enrollment 3. hepatitis b virus (hbv) carriers who fulfill one of the following criteria: seropositive of hbsag, or hbsag negative, but anti-hbc positive with hbv dna detectable defined as hbv dna \> 20 iu/ml (by roche taqman real time assay). 4. patients with alt ≤ 2 x uln (upper limit of normal) 5. normal cr mg/dl or egfr \> 80 ml/min 6. life expectancy \> 1 year 7. willing and able to provide written informed consent exclusion criteria: 1. females who are pregnant/nursing or with intention to be pregnant within the study period 2. documented hepatitis c virus (hcv) co-infection 3. patients with other current major systemic disease such as active infection, significant cardiac disease, poor control diabetes mellitus, osteopenia or osteoporosis that the investigators consider to be significant risk 4. current use of any hepatitis b prophylaxis medication 5. decompensated liver cirrhosis 6. current or previous use of any chemotherapy 7. use of any investigational product medicine within 1 month prior to the initiation of study treatment

Keywords: chronic hepatitis b hbv chemotherapy reactivation prophylaxis
duloxetine for major depression in peri-/postmenopausal women

Conditions: Major Depressive Disorder

Summary: the main objective of this study is to characterize a range of brain activation symptoms associated with major depression in peri- and post-menopausal women. also, assessing brain activation before and after the treatment might help to uncover some mechanisms associated with the pathophysiology of depression and menopause.

women approaching menopause and during the post-menopausal years appear to be at greater risk for developing major depressive episodes. moreover, this period in life has been associated with significant functional impairment due to the presence/severity of vasomotor symptoms (hot flashes, night sweats), cognitive complaints, and poorer quality of life. in light of recent controversies involving the use of hormone therapies, most physicians and patients are seeking nonhormonal strategies to alleviate menopause-related physical and emotional complaints. duloxetine has been shown to improve major depressive disorder (mdd) and menopause-related symptoms. to date, the effects of this agent on brain structure and functioning in midlife women with mdd have not been explored. the present study aims to investigate the effects of duloxetine on brain structure and functioning when used for the treatment of a major depressive episode in menopausal women using anatomical magnetic resonance imaging (mri) and functional mri (fmri). in addition, the investigators will examine whether the impact of treatment with duloxetine on vasomotor symptoms, cognition, and quality of life modulate the putative changes in brain structure and functioning.

Eligibility criteria:
inclusion criteria: * peri-/postmenopausal women, aged 40-60 year * moderate to severe major depressive episode exclusion criteria: * dsm-iv axis i diagnosis other than mdd * contraindications to magnetic resonance imaging * treatment-resistent * previous failed treatment with duloxetine * history of substance abuse or dependence in past year * serious suicidal risk * use of other psychotropic medications * electroconvulsive therapy or transmagnetic stimulation in past year * history of allergic reactions to duloxetine * significant laboratory abnormalities at baseline * severe hepatic impairment * end stage renal disease and undergoing dialysis * uncontrolled narrow-angle glaucoma * uncontrolled or untreated hyper-/hypothyroidism, or abnormal thyroid stimulating hormone concentration

Keywords: depression duloxetine menopause imaging fmri menopausal staging vasomotor symptoms
effect of different antihypertensive treatment on serum uric acid in newly diagnosed hypertensive patients

Conditions: Hypertension

Summary: assessment of the influence of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension patients.

hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately. thiazide-type diuretics, angiotensin-converting enzyme (ace) inhibitors and some of angiotensin-ii receptor blockers (arb) were reported to reduce renal excretion of urate and increased serum uric acid levels, beta-blockers also elevate serum uric acid levels. hyperuricemia is a risk factor for cardiovascular diseases. hyperuricemia was found to correlate with hypertension excluding the influence of other factors such as age and renal function. furthermore, many studies found that hyperuricemia was independently associated with cardiovascular events in patients treated with antihypertensive drugs. it is important to control serum uric acid levels in hypertensive patients treated with antihypertensive drugs in order to reduce the risk of gout and cardiovascular events. there is a gap in knowledge in studies showing the effect of antihypertensive drugs on serum uric acid in newly diagnosed hypertensive patients.

Eligibility criteria:
inclusion criteria: * all newly diagnosed hypertensive patients aged 30 years old and above will be invited to participate in this study exclusion criteria: 1. patients below 30 years old. 2. patients with kidney disease. 3. patients who are taking medications known to increase sua as (thiazide and loop diuretics, salicylates, cyclosporin use) or decrease the level of uric acid in the urine as (allopurinol, febuoxstate).
evaluation of pain and discomfort in the cardiac catheterization lab

Conditions: Patient Comfort

Summary: the purpose of this study is to explore how the timing of procedural sedation medications influences patient comfort and satisfaction with sedation. participation in this study will included be randomly assigned to one of two groups (long and short) within standard of care. each group will observe a time interval between receiving procedural sedation medications and the start of the procedure. a trained observer will evaluate patient experience during the procedure and at the end of the procedure we will ask the participant 3 brief questions about the experience. all other information collected about the experience during the procedure will occur as part of usual care. no further activities will be asked as part of this study. all study activities will occur during a scheduled visit and participation is complete once questions have been answered.


Eligibility criteria:
inclusion criteria: * english speaking * coming to duke university for cardiac catheterization exclusion criteria: -

Keywords: procedural sedation cardiac catheterization
effectiveness and safety of intradermal tranexamic acid injection as an adjunctive treatment for melasma in skin type iv - v

Conditions: Melasma

Summary: a double-blind, randomized, split-face controlled trial of 34 female patients with melasma was conducted. all subject were randomized to receive either intradermal tranexamic acid or placebo injection on the right or the left side of their face.

all subject were randomized to receive either 10 mg of intradermal tranexamic acid or placebo injection on the right or the left side of their face. the primary outcome was improvement of melasma lesions assessed by modified melasma area and severity index (mmasi) score and mexameter examination which includes melanin index (mi) and erythema index (ei). measurements were done at baseline and every two weeks for twelve weeks. additionally, side effects of therapy and subjects' satisfactory assessment with patient global assessment (ptga) were also documented.

Eligibility criteria:
inclusion criteria: * aged 18 to 60 years old * fitzpatrick skin type iv - v * diagnosed with melasma exclusion criteria: * pregnancy and breastfeeding * use of oral contraceptives within six months * use of topical or systemic melasma therapy within two weeks * history of superficial peeling within four weeks * history of dermabrasion within six months * use of photosensitizer drugs * history of thrombosis or currently using antithrombotic or anticoagulant drugs * history of ta allergy * experiencing any covid-19 symptoms

Keywords: melasma tranexamic acid modified melasma area and severity index melanin index erythema index
carbetocin at elective cesarean delivery part 4

Conditions: Postpartum Hemorrhage

Summary: postpartum hemorrhage (pph) is a major cause of maternal death worldwide. oxytocin is the most commonly used uterotonic drug to prevent and treat pph in north america. however oxytocin has a very short duration of action, requiring a continuous infusion to achieve sustained uterotonic activity. moreover large doses are associated with adverse effects like hypotension, nausea, vomiting, dysrhythmias and st changes. the society of obstetricians and gynecologists of canada (sogc) has recommended a single dose of 100 mcg of carbetocin at elective cesarean delivery to promote uterine contraction. in three studies recently performed at mount sinai hospital, the investigators have found no difference in uterine contractility between the doses of 20- 120 mcg carbetocin and that the ed90 is 14.8 mcg. thus a larger trial comparing the minimum effective dose determined in the previous three trials with the standard 100 mcg dose is necessary to confirm these findings.

the current oxytocin regimen requires the administration of a continuous infusion to achieve sustained uterotonic activity, which can be associated with a number of side effects and unpredictable efficacy. carbetocin in a single 100 mcg dose has apparently greater efficacy, with a similar side effect profile to that of oxytocin. in addition, some studies have also shown that there is less blood loss and less requirement for additional uterotonic drugs when carbetocin is administered. studies conducted by the investigators group at mount sinai have shown similar efficacy between the doses ranging from 20 to 100 mcg of carbetocin. in the investigators study, the investigators are going to compare those two doses of carbetocin to determine that 20 mcg is not inferior to 100 mcg to produce adequate uterine tone in elective cesarean delivery. this study will be a randomized, double - blind, non inferiority study.

Eligibility criteria:
inclusion criteria: * elective cesarean delivery under spinal anesthesia. * written informed consent to participate in this study. * term pregnancy exclusion criteria: * refusal to give written informed consent. * allergy or hypersensitivity to carbetocin or oxytocin. * conditions that predispose to uterine atony and postpartum hemorrhage, such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis. * hepatic, renal, and vascular disease.

Keywords: pregnancy postpartum hemorrhage cesarean delivery carbetocin
impact of hybrid-esd+ and liftup® on the en bloc/r0 rate in colorectal adenomas between 2 and 3 cm

Conditions: Colorectal Adenoma

Summary: this study examines whether the use of hybrid-esd+ with liftup (injection solution) results in a higher en bloc and/or r0 rate for non pedunculated colorectal adenomas between 2 and 3 cm than described in the literature for conventional emr.

there are several options for endoscopic polypectomy of polyps between 2-3 cm, all of which have their advantages and disadvantages and none of which has yet become the established standard procedure. conventional emr has the disadvantage of more frequent residuals and/or recurrences due to lack of en bloc resection, while esd has the disadvantage of being more complex and complications more likely. a possible alternative is the use of hybrid esd+ with liftup subcutaneous injection. the method with the liftup gel forming a stable gel cushion under the lesion, in combination with the circular circumcision of the mucosa at this site and the awc for the current loop and the grasper, could achieve a better en bloc resection rate with a low complication rate than other procedures mentioned above. the higher effectiveness in terms of recurrences and complications could subsequently result in a reduction of endoscopic or surgical re-interventions. in this study, non-pedunculated colorectal polyps between 2 and 3cm in size are resected using esd+ method and lift up as an injection solution. methodological and clinical parameters are recorded. after 4 weeks, the patients are contacted by telephone to record possible late effects. if an endoscopic control is performed after 6 months (according to the guideline or according to the investigator), the findings are also recorded.

Eligibility criteria:
inclusion criteria: * non-pedunculated lesion in the colorectum (epithelial lesion, 2-3 cm). * ablation medically indicated and possible (coagulation, etc. - as determined by the center) exclusion criteria: * age \< 18 years * pedunculated lesion (paris0-ip) * size of the lesion \ 3cm * pregnant and breastfeeding women * patient not capable of informed consent / consent not possible * bioptic evidence of a carcinoma / high probability of the presence of a carcinoma * non-lifting sign / known recurrence after previous therapy * impassable stenosis in the colon / rectum * patients with compelling need for therapeutic anticoagulation or dual antiplatelet therapy that cannot be discontinued for resection * as per contraindications from the awc \& liftup instructions for use: * the awc is not to be used if flexible-endoscopic procedures are contraindicated. * the liftup gel should not be used when flexible endoscopic procedures are contraindicated, especially in combination with submucosal endoscopic resection (emr) or endoscopic submucosal dissection (esd) injectables. * liftup gel should not be used in patients with known sensitivity to any of the ingredients.

Keywords: hybrid-esd+ endoscopic resection
german inclisiran network: retrospective registry of patients being treated with the sirna inclisiran in germany

Conditions: Hypercholesterolemia

Summary: the german inclisiran network is a registry of patients with hypercholesterinemia on treatment with the sirna inclisiran in germany

the aim of this retrospective, multi-center analysis is to use individual patient data to determine the extent of the variability in ldl-c reduction in response to inclisiran administration in a real-world setting.

Eligibility criteria:
inclusion criteria: * patients with elevated ldl-c levels (hypercholesterolemia) on stable lipid-lowering drugs for at least one month prior to the application of the sirna inclisiran * patients 18 years and older exclusion criteria: - patients who do not qualify for treatment with the sirna inclisiran according to the g-ba (gemeinsamer bundesausschuß) in germany.